News - Biotechnology, Licensing, GlaxoSmithKline


Epizyme earns $4 million milestone under GSK collaboration


US clinical-stage biopharma firm Epizyme announced the achievement of the lead candidate milestone for…


Amgen and GSK end marketing agreement for osteoporosis drug Prolia

Amgen and GSK end marketing agreement for osteoporosis drug Prolia


World leading independent biotech firm Amgen revealed in a Securities and Exchange Commission filing…


GlaxoSmithKline returns Duchenne drug rights to Prosensa

GlaxoSmithKline returns Duchenne drug rights to Prosensa


UK pharma giant GlaxoSmithKline says that its partner, Dutch biotech firm Prosensa has regained all rights…

BiotechnologydrisapersenGlaxoSmithKlineLicensingProsensaRare diseases

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring


US biotech firm Amicus Therapeutics saw its shares fall 4.2% to $2.03 by mid-morning trading on Thursday,…

Amicus TherapeuticsBiotechnologyCallidus BiopharmaFinancialGlaxoSmithKlineLicensingManagementMergers & AcquisitionsmigalastatRare diseases

Isis earns milestone payments from GlaxoSmithKline

Isis earns milestone payments from GlaxoSmithKline


US biotech firm Isis Pharmaceuticals says that UK pharma giant GlaxoSmithKline has added a development…

BiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsLicensingPharmaceuticalRare diseases

Immunocore in multi-million deal with GlaxoSmithKline on ImmTACs


Oxford, UK-based biotech firm Immunocore, focused on developing novel biological drugs called ImmTACs…


Elan pays $1 billion for a 21% share of Theravance royalties on four respiratory programs


US biotech firm Theravance (Nasdaq: THRX) has entered into a royalty participation agreement wherein…

Anoro ElliptaBiotechnologyBreo ElliptaElanFinancialGlaxoSmithKlineLicensingPharmaceuticalRespiratory and PulmonaryTheravance

GSK returns IPX066 rights to Impax; Merck & Co and Pfizer link up on diabetes drug


US biotech firm Impax Laboratories (Nasdaq: IPXL) saw its shares fall 2% to $17.32 in premarket trading,…

BiotechnologyDiabetesertugliflozinGlaxoSmithKlineImpax LaboratoriesIPX066LicensingMerck & CoNeurologicalPfizerPharmaceuticalResearch

Amgen in $180 mill deal with BIND; Priaxon accord with GlaxoSmithKline


BIND Biosciences, a US clinical stage investor backed company, and Amgen (Nasdaq: AMNG), the world's…

AmgenBIND BiosciencesBiotechnologyGlaxoSmithKlineLicensingOncologyPharmaceuticalPriaxon

NeRRe Therapeutics created to develop NRAs from GSK; GlycoVaxyn deal with GSK


NeRRe Therapeutics was launched in the UK yesterday to develop a portfolio of clinical and pre-clinical…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineGlycoVaxynLicensingNeRReTherapeuticsNeurologicalNovo NordiskPharmaceuticalResearchVaccines

Isis Pharma/GlaxoSmithKline's ISIS-TTR Rx gains US fast-track designation


In what has been a busy newsflow few days for USA-based Isis Pharmaceutical (Nasdaq: ISIS), the company…

BiotechnologyGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR.RXLicensingNorth AmericaPharmaceuticalRare diseasesRegulation

News briefs: Japan clears filgrastim biosimilar; GSK to up stake in Nigerian and Indian firms; UCB deals


Mid-sized Japanese drugmaker Mochida Pharmaceutical (TYO: 4534) says that it has received marketing…

Asia-PacificBiotechnologyExemed PharmaceuticalsFilgrastimFuji PharmaGlaxoSmithKlineLicensingMergers & AcquisitionsMochida PharmaceuticalNeupogenNewBridge PharmaceuticalsPharmaceuticalProductionRegulationRest of the WorldUCB

GlaxoSmithKline amends accord with Isis Pharma; gets FDA panel backing for raxibacumab


USA-based Isis Pharmaceuticals (Nasdaq: ISIS) says it has agreed to amend the clinical development plan…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR.RXLicensingNorth AmericaPharmaceuticalRare diseasesraxibacumabRegulationResearch

Biogen Idec sells Benlysta royalty rights to DRI for initial $18.3 million


US biotech firm Biogen Idec (Nasdaq: BIIB) has sold to a Canada-based DRI Capital managed fund its royalty…

BenlystaBiogen IdecBiotechnologyFinancialGlaxoSmithKlineHuman Genome SciencesLicensingPharmaceuticalRare diseases

Pharma partnering dollars continue to decline, Burrill & Co reports


The recent $3.4 billion partnering agreement announced in July between US pharma company Bristol-Myers…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbFinancialGlaxoSmithKlineHuman Genome SciencesLicensingMarkets & Marketing

Silencing investor concerns? Alnylam achieves RNAi milestone


US RNAi therapeutics specialties Alnylam Pharmaceuticals (Nasdaq: ALNY) has received a $3.2 million milestone…

Alnylam PharmaceuticalsAnti-viralsBiotechnologyFinancialGlaxoSmithKlineLicensingProductionVaccines

GlaxoSmithKline files for new eltrombopag indications in EU and USA; gains rights to derma products


UK pharma giant GlaxoSmithKline (LSE: GSK) revealed yesterday that it has submitted regulatory applications…

Anti-viralsBiotechnologyDermatologicalseltrombopagEuropeGlaxoSmithKlineLicensingNorth AmericaPharmaceuticalPromactaRegulationRevoladeStiefelWelichem Biotech

GlaxoSmithKline links with Japan's Chiome on MAbs


UK pharma giant GlaxoSmithKline group (LSE: GSK) and Tokyo, Japan-based biotech-venture company Chiome…

BiotechnologyChiome BioscienceGlaxoSmithKlineImmunologicalsLicensingOncologyPharmaceuticalResearch

Epistem in fibrosis research deal with GlaxoSmithKline


UK biotech and personalized medicines company Epistem (LSE:EHP) has entered into a three year biomarker…


Agenus expands deal with GlaxoSmithKline; Nuron in-licenses vaccines


US biotech firm Agenus (Nasdaq: AGEN) says it has amended the QS-21 license and manufacturing agreement…

AgenusAkshaya BioBiotechnologyGlaxoSmithKlineLicensingNuron BiotechPharmaceuticalVaccines

GSK exercises option for Galapagos drug candidates


Belgium-based Galapagos NV (Euronext: GLPG) says that its partner, UK pharma giant GlaxoSmithKline (LSE:…

Anti-Arthritics/RheumaticsBiotechnologyGalapagosGlaxoSmithKlineInflammatory diseasesLicensingPharmaceuticalResearch

Epizyme earns $4 million pre-clinical milestone from GSK under novel HMT therapeutics alliance


Privately-held US biotech startup Epizyme says it has achieved a pre-clinical milestones in its alliance…


Prosensa to get milestone payments from GSK under Duchenne collaboration


Dutch biotech company Prosensa, focusing on rare diseases with an unmet medical need, has agreed with…

BiotechnologyFinancialGlaxoSmithKlineLicensingPharmaceuticalProsensaRare diseasesResearch

Back to top